Global

Saving Lives for More Than a Century

Emil von Behring, an innovator with serum therapies who won the first Nobel Prize in Physiology and Medicine
CSL Behring and our parent company, CSL Limited, continue to build on a long legacy of innovation in patient care. CSL Behring traces its beginnings to the 1904 founding of Behringwerke, a company established by Emil von Behring, the first recipient of the Nobel Prize in Medicine. In 1916 our parent company, CSL Limited, was founded to supply vaccines to the people of Australia. During the 20th century, leading companies came together to form CSL Behring. For more than 60 years, we have specialized in providing plasma therapies to improve the quality of life for people with rare and serious diseases worldwide.

Our life-saving biotherapies are used to treat coagulation disorders, immune deficiencies, Alpha-1 antitrypsin deficiency, hereditary angioedema and hemolytic disease in newborns. Our biotherapies are also used during cardiac and transplant surgery, for wound healing and to treat shock, burns and sepsis.

CSL Behring. Providing biotherapies for life for more than a century.

 

1901Emil von Behring receives first Nobel Prize in Medicine
German doctor Emil von Behring receives the first Nobel Prize in Physiology and Medicine for his work on serum therapies. Von Behring's pioneering work results in the modern methods of immunization that have largely eradicated diphtheria worldwide.
1904Emil von Behring creates Behringwerke
Emil von Behring creates Behringwerke (a predecessor company) to produce sera and vaccines to combat infectious diseases.
1913Anti-infectious agents
Behringwerke expands to produce a gas gangrene antiserum and a cholera vaccine.
1940WWII: Largest supplier of albumin for U.S. military
Armour (a predecessor company) becomes the largest supplier of human albumin for the U.S. military during World War II.
1946Europe's first human plasma fractionation
Behringwerke is the first company in Europe to begin fractionating plasma proteins from human plasma on an industrial scale.
1949 ZLB established
The Zentrallaboratorium Blutspendedienst (ZLB), a predecessor company, is established in Bern as a department of the Swiss Red Cross and holds its first blood donor sessions in Switzerland.
1951 ZLB mandate to supply blood products
ZLB receives a mandate from the Swiss government to supply blood products through the Swiss Red Cross Blood Transfusion Service.
1951 Polio Immune Globulin
Armour Pharmaceuticals produced large quantities of polio immune globulin, a forerunner of the Salk polio vaccine, during the 1950s.
1954First pasteurized plasma protein solution
ZLB produces the first pasteurized plasma protein solution.
1955 Researchers discover Alpha-1
Alpha-1 antitrypsin, a proteinase inhibitor, is discovered, purified and characterized for the first time by researchers of Behringwerke.
1962 New fractionation process provides better yield
Kistler and Nitschmann, researchers with ZLB, develop a new plasma fractionation method that provides significantly better yields of the valuable proteins isolated from human plasma.
1970Japan's first IVIg
Behringwerke launches Gamma-Venin®, the first intravenous immune globulin (IVIg) product in Japan.
1979 Launch of first purified IVIg
ZLB and Sandoz AG, Switzerland, launch Sandoglobulin®, the world’s first purified immunoglobulin product for intravenous infusion.
1981Launch of first pasteurized factor VIII therapy
Behringwerke (a predecessor company) introduces Haemate® human plasma coagulation factor VIII/von Willebrand factor complex, first marketed in Europe for the treatment of patients with hemophilia A. It is the first pasteurized factor VIII product in the world.
1984First IVIg approved in U.S.
ZLB receives approval for polyvalent immunoglobulin – the first IVIg product to be approved in the United States.
1986Humate-P® approved in U.S.
FDA approves Humate-P® human coagulation factor VIII/von Willebrand factor complex for the prevention and control of hemorrhagic episodes in patients with hemophilia A.
1988 First fibrin sealant launched in Japan
Behringwerke launches Beriplast® P, the first fibrin sealant in Japan.
1990 Monoclate®-P launched
Monoclate®-P, the second generation form of Monoclate Factor VIII using monoclonal antibody technology, adds pasteurization as an additional viral removal step.
1992 Mononine® approved in U.S.
FDA approves Mononine®, a monoclonal antibody purified Factor IX product for treatment of hemophilia B. Mononine® was the first highly purified FIX in the U.S. market and is still the gold standard.
1993Helixate® approved in U.S.
The FDA approves Helixate® recombinant coagulation factor VIII for the treatment of hemophilia A.
1996 Armour and Behringwerke become Centeon
Centeon (a predecessor company) is formed as 50/50 joint venture between Armour Pharmaceuticals and Behringwerke. At the time, Armour was owned by Rhone-Poulenc Rorer and Behringwerke was owned by Hoechst AG.
1996 Rhophylac®, world’s first liquid anti-D immunoglobulin,launched
Rhophylac® is launched as the world’s first liquid anti-D immunoglobulin for the prevention of hemolytic disease in newborns due to Rh factor incompatibility.
1998€50 million plant modernization
A major, 50 million euro capital project is completed to modernize production facilities in Marburg, Germany.
1999 Centeon becomes Aventis Behring
Centeon changes its name to Aventis Behring (a predecessor company) when its parent companies Rhone-Polenc Rorer (RPR) and Hoechst AG merge to become Aventis.
1999 First von Willebrand factor in U.S.
FDA approves Humate-P® human coagulation factor VIII/von Willebrand factor complex for treatment of von Willebrand disease, the most common hereditary bleeding disorder.
2000New formulation of recombinant Factor VIII
Helixate® FS/ Helixate® NexGen recombinant coagulation factor VIII, formulated with sucrose for the treatment of hemophilia A, is approved by the FDA for use in U.S. and by the EMEA for use in 15 countries.
2000 ZLB Bioplasma established
CSL acquires ZLB Blood Transfusion Service (ZLB Zentrallaboratorium) from the Swiss Red Cross to establish ZLB Bioplasma (a predecessor company), headquartered in Bern, Switzerland.
2000Gettin' in the Game launched
Gettin' in the Game, a healthy living program that promotes the value of exercise for children with bleeding disorders is launched. Program continues to this day.
2001 ZLB Plasma Services established
CSL acquires 47 plasma collection centers and laboratory facilities operated by Nabi Plasma Collection Centers (U.S.) and creates ZLB Plasma Services, now CSL Plasma.
2001World's largest plasma collection business
Aventis Behring acquires 42 plasma centers from Serologicals, forming the world's largest plasma collection business.
2002Junior National Championships (JNC)
The company launches Junior National Championships in partnership with the National Hemophilia Foundation to promote the value of exercise for children with bleeding disorders.
2003Carimune® NF launched in U.S.
The company begins marketing Carimune® NF, the first nanofiltered human normal immunoglobulin for intravenous (IV) administration, in the United States.
2003Zemaira® approved in U.S.
FDA approves Zemaira® human Alpha-1 proteinase inhibitor for individuals with Alpha-1 proteinase inhibitor deficiency and clinical evidence of emphysema.
2003Assurance Program launched
The Assurance Program is launched to ensure that people who rely on our recombinant and plasma-derived therapies can continue to receive these vital treatments even if they experience a lapse in third-party, private health insurance.
2004 ZLB Behring established
CSL completes the acquisition of Aventis Behring, combining it with ZLB Bioplasma to create ZLB Behring, today known as CSL Behring.
2004EMEA approves Mononine®
The EMEA approves Mononine® human coagulation factor IX concentrate as the first product to treat hemophilia B patients undergoing surgery, exposed to trauma, or experiencing severe, spontaneous hemorrhage.
2005Mix2Vial™ introduced
Mix2Vial™ is introduced as an alternate transfer device, offering a new way to reconstitute products.
2006Groundbreaking: state-of-the-art Ig plant
Construction begins on a new immunoglobulin manufacturing plant at the company's Bern, Switzerland facility.
2006 Vivaglobin® approved in U.S. and U.K.
Vivaglobin® licensed for use in adults and children who require antibody replacement due to primary immunodeficiency in U.K. and U.S. Vivaglobin® was the first FDA-approved subcutaneous immunoglobulin (SCIg) treatment.
2006State-of-the-art plant licensed by FDA
Highly automated facility in Kankakee, Illinois to allow for increased production of Zemaira®.
2006Humate-P® 50% volume reduction
Humate-P® human coagulation factor VIII/von Willebrand factor complex is now available featuring a smaller diluent – 50 percent less in all assay sizes, shortening infusion time and requiring less storage space.
2006 Cytogam® acquired
Cytogam®, an IVIg enriched with antibodies against cytomegalovirus – the most common cause of life-threatening infection occurring in patients with solid organ transplants – is acquired by company.
2006 Two Ig formulations available in Canada
With the approvals of Sandoglobulin® NF Liquid IVIg and Vivaglobin® subcutaneous Ig in Canada, the company now offers two formulations of immunoglobulin for people with primary immune deficiency.
2007 ZLB Behring becomes CSL Behring
As part of a global brand alignment, ZLB Behring changes its name to CSL Behring.
2007 Privigen® approved by FDA
The U.S. Food and Drug Administration grants marketing approval for Privigen®, the first proline-stabilized intravenous immunoglobulin (IVIg), for treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura.
2007 Rhophylac® approved for ITP in U.S.
U.S. Food and Drug Administration approves Rhophylac® for additional indication – the treatment of immune thrombocytopenic purpura (ITP).
2008 Professor Heimberger research award established
CSL Behring establishes a research award to recognize the next generation of coagulation specialists. Award named in honor of the late Behringwerke employee and pioneering hemophilia specialist, Dr. Norbert Heimberger. While at Behringwerke, Dr. Heimberger discovered a novel method for plasma-protein pasteurization.
2008 Mutual Recognition Procedure for Berinert® P completed
Berinert® P approved for use in 20 additional countries in Europe. European countries to help people suffering from hereditary angioedema.
2009 Orphan-drug exclusivity granted to RiaSTAP®
U.S. Food and Drug Administration (FDA) granted CSL Behring seven-years of orphan-drug exclusivity for RiaSTAP®, the first FDA-approved treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency.
2009 New Ig Lab Plant approved in Bern, Switzerland
FDA, EMEA, Swissmedic and TGA approve new state-of-the-art immunoglobulin manufacturing plant at Bern, Switzerland manufacturing facility.
2009 CSL Plasma opens state-of-the-art laboratory
ZLB Plasma changes its name to CSL Plasma to align with its parent company, CSL Behring, and opens one of the world's largest and most advanced plasma testing laboratories in Knoxville, TN.
2009 CSL Behring gives $2 million to WFH GAP Program
To advance the diagnosis and treatment of hemophilia in developing countries, CSL Behring donates $2 million USD worth of coagulation factor to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) program for a three-year period.
2009 NORD honors CSL Behring with rare disease award
National Organization for Rare Disorders (NORD) recognizes CSL Behring for developing and marketing RiaSTAP®, the U.S.'s first and only treatment for acute bleeding episodes in patients with congenital fibrinogen deficiency, an extremely rare, potentially life-threatening bleeding disorder.
2009 CSL Behring receives Tell Award for Innovation
CSL Behring awarded the Swiss government's Tell Award for the most significant innovative technology investment in 2008. This award recognizes CSL Behring's exceptional innovations in state-of-the-art manufacturing and novel protein therapies.
2009 Berinert®, first therapy for acute attacks of HAE in U.S.
The U.S. Food and Drug Administration (FDA) granted marketing approval for Berinert® C1-esterase inhibitor, the country's first and only therapy for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE).
2010 Hizentra®, first and only 20 percent SCIg, approved by FDA
The U.S. Food and Drug Administration (FDA) granted marketing approval for Hizentra®, the first and only 20 percent subcutaneous immunoglobulin (SCIg). In the US, Hizentra is indicated for the treatment of patients with primary immune deficiency. Hizentra is also in registration in the EU and Switzerland. Stabalized with L-proline, Hizentra is ready to use; it requires no refrigeration throughout its 30-month shelf-life, offering patients and physicians convenience and portability.
2011 FDA approves Corifact™, first and only FXIII concentrate approved in U.S.
The U.S. Food and Drug Administration (FDA) granted marketing approval for Corifact™ for the treatment of congenital factor XIII (FXIII) deficiency. Congenital FXIII deficiency is a rare and potentially life-threatening bleeding disorder that affects an estimated 1 person in 2 million. Corifact is also available in 12 countries under the trade name Fibrogammin®.
2011 FDA Approves Expansion of Hizentra® Production Facility in Bern
Capacity to produce Hizentra® more than doubles following FDA approval of expansion of innovative production facility in Bern.
2011 European Commission Grants Marketing Authorization for Hizentra®
Hizentra® receives marketing authorization, valid for all 29 European/European Economic Area member states, for treating people diagnosed with primary immunodeficiency as well as secondary immunodeficiencies.
2012 CSL Behring receives 2012 EURORDIS Award
The European Organisation for Rare Disorders recognized CSL Behring for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions with the 2012 EURORDIS Award.
2013 FDA approves Kcentra® for urgent warfarin reversal
In April, the U.S. Food and Drug Administration (FDA) granted marketing approval for Kcentra® to reverse the effects of warfarin in adult patients with acute major bleeding. In December, Kcentra® was also approved for warfarin reversal in patients needing an urgent surgery or other invasive procedure. CSL Behring markets Kcentra® as Beriplex® or Confidex® in more than 25 countries.
2014 CSL Behring expands Kankakee facility by 140,000 square feet
The expansion received approval from the U.S. Food & Drug Administration to commence operations, significantly increasing plasma processing and albumin production capacity.
2015 CSL Behring receives NHF 2015 Corporate Leadership Award
The National Hemophilia Foundation awarded CSL Behring its 2015 Corporate Leadership Award for delivering on its promises to the bleeding disorders community.
2016 IDELVION® approved in multiple markets
IDELVION®, CSL Behring’s recombinant albumin fusion protein forhemophilia B, was granted marketing authorization in the U.S., European Union and Canada. IDELVION® delivers high-level protection from bleeds with up to 14-day dosing in appropriate patients, with a median annualized spontaneous bleeding rate (AsBR) of 0.00.

FDA approves AFSTYLA®
AFSTYLA®, the first and only single-chain recombinant factor VIII product for hemophilia A, received FDA approval. AFSTYLA® is specifically designed for long-lasting protection from bleeds with two to three times weekly dosing.

Share
LinkedIn Twitter Facebook Google+